Trials / Completed
CompletedNCT06635252
Statins, Cholesterol and Cognitive Decline in Alzheimer's
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,000 (actual)
- Sponsor
- Karolinska Institutet · Academic / Other
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
Disturbances in brain cholesterol homeostasis may be involved in the pathogenesis of Alzheimer's disease (AD). Lipid-lowering medications could interfere with neurodegenerative processes in AD through cholesterol metabolism or other mechanisms. The investigators aim to estimate the causal effect of statins on cognitive function measured by MMSE and to identify the mediating or modifying effect of cholesterol between statins and cognitive function in patients with Alzheimer's disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | STA 4783 | Use of statins will be identified from Prescribed Drug register within 6 months before dementia diagnosis or each follow-up date |
Timeline
- Start date
- 2025-01-01
- Primary completion
- 2025-03-01
- Completion
- 2025-03-01
- First posted
- 2024-10-10
- Last updated
- 2025-05-02
Locations
1 site across 1 country: Sweden
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06635252. Inclusion in this directory is not an endorsement.